Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

Elucidating Cooperative Genetic Events in DCIS Progression in Mutant p53-Driven Breast Cancer

January 9, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Overexpression of TMEM267, which encodes a transmembrane protein overexpressed in 22% of TP53 missense mutant breast cancer cases, in cells with mutant TP53 caused a significant increase in the filled duct, DCIS-like phenotype.

TRMT112 Drives a Tumor Growth and Metastasis-Promoting Program in Triple-Negative Breast Cancer

January 9, 2026

[Cell Death & Differentiation] Functional assays demonstrated that tRNA methyltransferase activator subunit 11-2 (TRMT112) knockdown in TNBC cells significantly reduces proliferation, migration, invasion, and metastatic potential, whereas its overexpression enhanced these tumorigenic properties.

Bioactive Glass Nanoparticles Induce Intrinsic P53-Dependent Apoptosis and Promote Genomic Instability via ROS Overproduction and Mitochondrial Depolarization in Triple-Negative Breast Cancer Cells

January 8, 2026

[Scientific Reports] Scientists investigated the therapeutic efficacy and molecular mechanisms of bioactive glass nanoparticles in highly aggressive triple-negative MDA-MB-231 breast cancer cells.

Oncogenic and Immunological Roles of NSUN2 in Triple Negative Breast Cancer

January 8, 2026

[Scientific Reports] The authors found that NSUN2 was highly expressed in pan-cancer, and elevated levels correlate with poor prognosis in TNBC.

MAZ-Mediated Ubiquitin-Conjugating Enzyme E2C Upregulation Promotes Breast Cancer Progression via the MAPK Signaling Pathway

January 8, 2026

[Translational Oncology] Researchers highlighted the critical role of the MAZ/UBE2C/MAPK signaling axis in the progression of breast cancer and identify potential novel therapeutic targets for its treatment.

First Functional Evidence That a Rare Germline TP53β Variant Drives Senescence-Associated Immune Suppression and Impairs Apoptosis and Cell Migration in Breast Cancer Patients

January 8, 2026

[Translational Oncology] Investigators provided supporting evidence for the pathogenicity of the TP53β N340D variant highlights the importance of integrating functional genomics into PSGT to enhance medical decision-making.

Inhibition of GPX4 Induces the Death of P53-Mutant Triple-Negative Breast Cancer Cells

January 8, 2026

[Breast Cancer Research and Treatment] Researchers demonstrated that TP53-mutant TNBC cells have unique survival pathways that can be effectively targeted.

Targeting the NAT10-HDAC4 Positive Feedback Loop Counteracts Immunosuppression in Breast Cancer

January 8, 2026

[Journal of Experimental & Clinical Cancer Research] Scientists identified a self-reinforcing NAT10/HDAC4 signaling circuit that drives breast cancer progression and immune evasion.

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast Cancer

January 8, 2026

[Cancer Research] The authors identified enrichment of dysregulated replication stress and DNA damage responses in multiple ESR1 mutant models.

Replication Stress-Inducing ELF3 Upregulation Promotes BRCA1-Deficient Breast Tumorigenesis in Luminal Progenitors

January 8, 2026

[Elife] Using single-cell sequencing of human BRCA1 mutant breast cancers and RNA sequencing of BRCA1-deficient normal mammary cells, scientists revealed that replication stress was a feature of luminal progenitor cells and a driving factor during BRCA1-associated tumorigenesis.

Precision Nanotechnology: Revolutionizing Therapeutic Strategies against Drug-Resistant Breast Cancer

January 8, 2026

[Annals of Biomedical Engineering] The authors offer a thorough analysis of various drug resistance mechanisms, going into great detail into the molecular, cellular, and genetic contributors.

AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)

January 8, 2026

[AccuStem Sciences, Inc. ] AccuStem Sciences, Inc. announced the execution of a pilot study agreement with NSABP to evaluate StemPrintER in a subset of patients from the B-32 cohort. The StemPrintER test interrogates 20 genes to stratify patients with early stage breast cancer according to their recurrence risk.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.